Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  tamoxifen citrate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 412 for your search:
Start Over
Tamoxifen Pharmacogenetics and Clinical Effects
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Completed
Age: 18 to 70
Sponsor: NIGMS
Protocol IDs: 0208-14, UO1-GM61373-05, NCT00228930
Arimidex Observational: Reason for and Effect of Change From Tamoxifen
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5392NL0002, ARREST, NCT00246961
Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Completed
Age: 18 to 63
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3068A1-400, NCT00418236
Liver Safety Under Upfront Arimidex vs Tamoxifen
Phase: Phase IV
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5392L00023, NCT00537771
Pharmacology of Adjuvant Hormonotherapy in Breast Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09 SEIN 09, NCT01127295
Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11 SEIN 09, NCT01553903
Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11SEIN12, NCT01612871
Phase II/III Chemotherapy and Hormone Therapy with ADR/VCR/DBD/PRED Followed by TMX/FXM/BLEO/HMM/MTX-CF for Metastatic Stage III/IV or Recurrent Breast Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 65
Sponsor:
Protocol IDs: WCCC-CO-7711R, NCI-D80-048-183
Phase II/III Chemotherapy with CTX/ADR/5-FU/MTX with and without Cell Synchronization with Tamoxifen and Premarin for Metastatic Breast Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 65
Sponsor:
Protocol IDs: NCI-76-C-377A, NCI-MB-160A
Phase II/III Chemotherapy with CTX/ADR/MTX/5-FU, with vs without Hormonal Synchronization with TMX/Premarin, for Metastatic Mammary Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: NCI-76-C-377B, NCI-MB-160B
Phase II/III Randomized Study of TMX/FXM vs TMX/Danazol for Metastatic Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: no age specified
Sponsor: NCI
Protocol IDs: NCI-81-C-72, NCI-MB-153, NCI-T83-1460N, T83-1460
Phase II/III Therapy with TMX vs TMX/FXM for Locally Inoperable, Recurrent, or Metastatic Carcinoma of the Breast
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: NCCTG-813251, MAYO-813251, NCCTG-81-32-51
Phase II/III Multimodality Therapy with Surgery, CTX/ADR/5-FU/TMX/FLU, plus Radiotherapy for Stage III Breast Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 69
Sponsor:
Protocol IDs: WCCC-CO-8111, NCI-D81-048-515
Phase II/III Endocrine Therapy with AG/TMX/HC vs TMX Alone for Metastatic or Recurrent Breast Carcinoma, with AG/HC for Patients with Prior TMX
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: postmenopausal
Sponsor:
Protocol IDs: MAYO-803201
Phase II/III Pilot Study of Endocrine Therapy with Tamoxifen vs Tamoxifen plus Aminoglutethimide in Premenopausal Patients with Metastatic Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 55
Sponsor: NCI
Protocol IDs: DFCI-79049, NCI-T84-0176D, T84-0176
Phase II/III Randomized Comparison of DTIC/BCNU/CDDP vs DTIC/BCNU/CDDP/TMX vs CDDP/TMX in Patients with Disseminated Malignant Melanoma
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: UCSD-88612, NCI-V89-0023
Phase III Randomized Study of Adjuvant Chemotherapy with High-Dose Doxorubicn/Cyclophosphamide vs Doxorubicin Followed by Cyclophosphamide in Women with High-Risk Breast Cancer and 0-3 Positive Nodes
Phase: Phase III
Type: Treatment
Status: Closed
Age: adult
Sponsor: NCI
Protocol IDs: SWOG-9313, CLB-9394, E-S9313, NCCTG-933051, INT-0137
Start Over